panaloko club
Here are the billionaires stocking Trump’s next administration
West Vancouver Emergency Services Gift Drive returns collecting toys for families in needControl Towers Market Optimizing Supply Chain Visibility with Advanced Analytics Solutions
ResMed Inc. stock falls Wednesday, underperforms marketFalcons QB Cousins is looking to avoid interceptions, have bounce-back game in Minnesota homecoming
Bethlehem marks a second subdued Christmas Eve during the war in GazaWhy Domo (DOMO) Stock Is Trading Lower TodayS&P/TSX composite up on shorter Christmas Eve session, U.S. markets also rise TORONTO — Broad-based gains led Canada's main stock index to close higher in the shortened Christmas Eve trading session while U.S. stock markets also rose. The S&P/TSX composite index ended up 97.84 points at 24,846.82. Canadian Press Dec 24, 2024 10:56 AM Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message A signboard is displayed at the TMX in Toronto, Wednesday, Nov. 1, 2023. THE CANADIAN PRESS/Chris Young Listen to this article 00:01:33 TORONTO — Broad-based gains led Canada's main stock index to close higher in the shortened Christmas Eve trading session while U.S. stock markets also rose. The S&P/TSX composite index ended up 97.84 points at 24,846.82. In New York, the Dow Jones industrial average was up 390.08 points at 43,297.03. The S&P 500 index was up 65.97 points at 6,040.04, while the Nasdaq composite was up 266.24 points at 20,031.13. The Canadian dollar traded for 69.51 cents US compared with 69.47 cents US on Monday. The February crude oil contract was up 86 cents at US$70.10 per barrel and the February natural gas contract was up 16 cents at US$3.50 per mmBTU. The February gold contract ended up US$7.30 at US$2,635.50 an ounce and the March copper contract was up two cents at US$4.11 a pound. This report by The Canadian Press was first published Dec. 24, 2024. Companies in this story: (TSX:GSPTSE, TSX:CADUSD) The Canadian Press See a typo/mistake? Have a story/tip? This has been shared 0 times 0 Shares Share by Email Share on Facebook Share on X Share on LinkedIn Print Share via Text Message More National Business Stock market today: Wall Street rallies ahead of Christmas Dec 24, 2024 10:12 AM YVR janitors suspend strike escalation after tentative deal Dec 24, 2024 9:30 AM Border measures aimed at responding to Trump's tariff threat begin to take effect Dec 24, 2024 8:17 AM Featured Flyer
MARKET REPORT: Protein drink company bulks up on fresh rating By JON HOPKINS Updated: 22:00, 4 December 2024 e-mail View comments Shares in protein drink maker Applied Nutrition were given a tonic yesterday after analysts at Deutsche Bank said investors should ‘bulk up’ on the stock. The company, founded by Liverpool scaffolder Thomas Ryder, has been losing weight as it drifted lower following its market debut in October. But it was given a boost by Deutsche analysts. The German bank, whose Numis UK business was the sponsor for the Applied Nutrition offering, started the stock with a ‘buy’ rating and a 180p target. In its first ten years, Deutsche pointed out, the company grew quickly by leveraging production and innovation capabilities. And its focus on innovation is a clear differentiator, allowing it to grow ahead of the wider sports nutrition market, which is globally estimated to be worth £189billion. Having floated at 140p on October 24, shares have been on a rollercoaster ride – hitting 150p on the first day but later falling as low as 135p before see-sawing yesterday to close 0.7 per cent, or 1p, higher at 136p. Applied Nutrition, founded by Liverpool scaffolder Thomas Ryder (pictured), has been losing weight as it drifted lower following its market debut in October AIM-listed Science in Sport, which has been hoping for a re-rating based on the Applied Nutrition float, held steady at 26.5p. There was no bulking up for the FTSE 100, which closed 0.3 per cent, or 23.60 points, lower at 8335.81 although the FTSE 250 managed to gain 0.5 per cent, or 112.41 points, to 21,005.15. Broker comment supported British Airways owner IAG, up 4.1 per cent, or 10.7p, to 175.1p as analysts at JP Morgan said it was their most compelling overweight in the airline sector and added the stock to the ‘analyst focus list’. Elsewhere, soft drinks bottler Coca-Cola HBC added 1.3 per cent, or 36p, to 2854p after analysts at BNP Exane upgraded its rating to ‘outperform’, while packaging firm Bunzl gained 0.3 per cent, or 10p, to 3610p despite being downgraded to ‘hold’ by analysts at HSBC. Legal & General topped the FTSE 100 gainers, up 6 per cent, or 13.4p, to 236.3 as the insurer maintained full-year profit guidance and hinted at more returns for shareholders. Meanwhile, Vistry had a dead cat bounce, gaining 4.9 per cent, or 30.5p, to 658.5p even as the housebuilder’s demotion from the FTSE 100 was confirmed. RELATED ARTICLES Previous 1 Next Boost for FTSE as investors pile into UK shares: But £317m... Gold miner backed by property tycoon Nick Candy snaps up... Share this article Share HOW THIS IS MONEY CAN HELP How to choose the best (and cheapest) stocks and shares Isa and the right DIY investing account It will be joined in the FTSE 250 next month by retailers Frasers and B&M, with Games Workshop, wealth manager St James’ Place and investment trust Alliance Witan replacing them. Victrex was the biggest riser on the FTSE 250 – up 10 per cent, or 100p, to 1104p – thanks to an upgrade to ‘buy’ from analysts at Jefferies. But trading news weighed on Zigup, the former Redde Northgate corporate vehicle hire group, which dropped 12.9 per cent, or 49.5p, to 333.5p after a drop in first-half profits and revenue. Among the small caps, Biome fell 14.3 per cent, or 0.75p, to 4.5p as the bioplastics firm warned on full-year profitability. But miner Tungsten West rose 16.7 per cent, or 0.5p, to 3.5p after appointing Stephen Harrison non-executive chairman. And Fusion Antibodies gained 39.3 per cent, or 1.65p, to 5.85p after news merged that it has had a grant application approved. Stock Watch - Scancell Scancell jumped 3.9 per cent, or 0.5p, to 13.5p after the biotech firm did a deal with US firm Genmab worth up to £497million. The agreement grants global rights to develop and commercialise an antibody from Scancell’s Glymab platform. It includes sums tied to development, regulatory and commercial goals, and follows evaluation that showed the antibody can generate highly tumour-specific antibodies for therapeutic development. DIY INVESTING PLATFORMS AJ Bell AJ Bell Easy investing and ready-made portfolios Learn More Learn More Hargreaves Lansdown Hargreaves Lansdown Free fund dealing and investment ideas Learn More Learn More interactive investor interactive investor Flat-fee investing from £4.99 per month Learn More Learn More Saxo Saxo Get £200 back in trading fees Learn More Learn More Trading 212 Trading 212 Free dealing and no account fee Learn More Learn More Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence. Compare the best investing account for you Share or comment on this article: MARKET REPORT: Protein drink company bulks up on fresh rating e-mail Add comment Some links in this article may be affiliate links. If you click on them we may earn a small commission. That helps us fund This Is Money, and keep it free to use. We do not write articles to promote products. We do not allow any commercial relationship to affect our editorial independence.